Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4566 results
X-Chem, AstraZeneca expand drug discovery partnership
X-Chem, a small molecule discovery specialist, has expanded its existing global drug discovery and technology transfer collaboration with AstraZeneca.
Drug Research > Drug Discovery & Development > News
Carmot Therapeutics secures funding for type 2 diabetes drug
Carmot Therapeutics, a biotechnology company, has closed a $15m financing to support the development of its type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept.
Drug Research > Drug Discovery & Development > News
Avacta signs licensing deal with Glythera after successful trial
Avacta Group has signed a licensing agreement with Glythera for its Affimer technology after a successful proof-of-concept study.
Drug Research > Drug Discovery & Development > News
Telix Pharmaceuticals establishes Japanese subsidiary
Australian biopharmaceutical firm Telix Pharmaceuticals has established Telix Pharmaceuticals (Japan) (Telix Japan) and appointed first two members of the Japanese leadership team.
Drug Research > Drug Discovery & Development > News
Google venture unit supports UK flu vaccine firm Vaccitech
By PBR Staff Writer
UK-based Vaccitech, which is developing a universal influenza vaccine and other vaccine-related products, has bagged £20m ($27.1m) of funding from various investors.
Drug Research > Drug Discovery & Development > News
New reusable treatment can destroy cancer cells more effectively and selectively
By PBR Staff Writer
Researchers from the University of Warwick have developed a new approach, using a substance found in stinging nettles & ants, to destroy cancer cells more effectively and selectively.
Drug Research > Drug Discovery & Development > News
Ablynx rejects EUR2.6bn takeover offer from Novo Nordisk
By PBR Staff Writer
Ablynx has rejected a takeover proposal of around €2.6bn from Novo Nordisk, calling it as unsolicited and it fundamentally undervalues the company.
Drug Research > Drug Discovery & Development > News
Celgene to acquire Impact Biomedicines for about $7bn
By PBR Staff Writer
Global biopharmaceutical firm Celgene has agreed to acquire Impact Biomedicines in a deal worth about $7bn.
Drug Research > Drug Discovery & Development > News
Takeda proposes to buy cell therapy firm TiGenix for EUR520m
By PBR Staff Writer
Takeda Pharmaceutical has offered to acquire Belgium-based cell therapy company TiGenix for €520m to expand its late-stage gastroenterology pipeline and its footprint in the US specialty care market.
Drug Research > Drug Discovery & Development > News
BioNTech raises $270m in new round of funding
BioNTech, a company focused on developing personalized immunotherapies for cancer, has completed a $270m Series A round of financing.
Drug Research > Drug Discovery & Development > News
Sangamo, Pfizer collaborate to develop zinc finger protein gene therapy for ALS
Sangamo Therapeutics and Pfizer have collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
Drug Research > Drug Discovery & Development > News
NovaQuest Capital to buy Viamet Pharmaceuticals
NovaQuest Capital Management has agreed to acquire Viamet Pharmaceuticals, including its product candidate, VT-1161, which has completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection.
Drug Research > Drug Discovery & Development > News
Pear secures $50m funding to advance prescription digital therapeutics platform
Digital health firm Pear Therapeutics has completed a $50m Series B financing led by Singapore-headquartered investment firm Temasek.
Drug Research > Drug Discovery & Development > News
Summit signs deal with Eurofarma for Latin American rights to Ridinilazole
Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.
Drug Research > Drug Discovery & Development > News
vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei
vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.
Drug Research > Drug Discovery & Development > News
1-15 of 4566 results